Clinical Trials Browser

Interventional × Cholangiocarcinoma × Specimen Handling × Clear all

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

Clinical Trials

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer